Biganib

Brigatinib (Brigatinib) Instructions

Common name: Brigatinib

Trade name: Brigatinib

All names: Brigatinib, Brigatinib, Cabunin Brigatinib, Alunbrig, brigatinib, AP26113, Briganix

Brukitinib Indications and Uses

Brugetinib is a kinase inhibitor suitable for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib.

Brugibine dosage and administration

90 mg orally once daily for the first 7 days, increasing to 180 mg orally once daily if tolerated. Can be taken with or without food.

Bukitibine dosage forms and specifications

Tablets: 30 mg and 90 mg

Bukitibine contraindications

None.

Brugibine Warnings and Precautions

Interstitial Lung Disease (ILD)/Pneumonitis: Occurred in 9.1% of patients at the recommended dose. Monitor for new or worsening respiratory symptoms, especially during the first week of treatment. Withhold bucitabine for new or worsening respiratory symptoms and promptly evaluate ILD/pneumonitis. Upon recovery, either reduce dose or permanently discontinue brigatinib.

Hypertension: Monitor blood pressure for 2 weeks after treatment and at least monthly thereafter. For severe hypertension, withhold brigatinib and then reduce dose or permanently discontinue.

Bradycardia: Monitor heart rate and blood pressure regularly during treatment. If symptomatic, withhold brigatinib and then reduce dose or permanently discontinue.

Visual Impairment: Advise patients to report visual symptoms. Withhold bukitabine and obtain ophthalmological evaluation, then reduce dose or permanently discontinue bukitabine

Creatine phosphokinase (CPK) elevation: Monitor CPK levels regularly during treatment. Depending on the severity, withhold bukitabine and then resume or reduce dose.

Elevated pancreatic enzymes: Monitor lipase and amylase levels regularly during treatment. Depending on the severity, withhold bukitabine and then resume or reduce dose.

Hyperglycemia: Assess fasting serum glucose prior to initiation of bukitabine and routinely during treatment. If not controlled with optimal medical management, withhold brigibine and, depending on severity, consider dose reduction or permanent discontinuation.

Embryo-fetal toxicity: May cause fetal harm. Advise females of reproductive potential of the potential risks to the fetus. and use of non-hormonally effective contraceptive methods.

Adverse reactions of brigatinib

The most common adverse reactions (≥25%) with brigatinib are nausea, diarrhea, fatigue, cough, and headache.

Brugatinib Drug Interactions

CYP3A Inhibitors: Avoid concomitant use of brigatinib with strong CYP3A inhibitors. Concomitant use of a strong CYP3A inhibitor cannot be avoided. Reduce the dose of brigatinib.

CYP3A Inducers: Avoid the concomitant use of brigibine and strong CYP3A inducers.

CYP3A substrates: Hormonal contraceptives may be ineffective due to reduced exposure.

Brigatinib is used in special groups

Breastfeeding: Breastfeeding is not recommended.